5 Key Takeaways

• 1

  Patients with asthma treated with dupilumab or tezepelumab had similar exacerbation rates, with 22% experiencing at least one episode.

• 2

  Dupilumab users had slightly higher systemic corticosteroid use (45%) compared to tezepelumab users (41%).

• 3

  Adverse events were reported in 24% of dupilumab patients and 18% of tezepelumab patients, with dermatitis and conjunctivitis being the most common.

• 4

  Eosinophil levels decreased in both treatment groups, with greater but nonsignificant reductions in the dupilumab cohort.

• 5

  The study included 949 matched patients per cohort and was limited by its retrospective design and reliance on electronic health records.